A Phase 2 interventional study of Osilodrostat in Cushing's Syndrome, Ectopic Corticotropin Syndrome and Adrenal Adenoma, sponsored by Novartis Pharmaceuticals. Completed at 4 sites in Japan. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-05-06.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study aim was to investigate the efficacy and safety of Osilodrostat in patients with Cushing's syndrome due to causes other than Cushing's disease in Japan.
This was a Phase II, single arm, open-label, dose titration, multi-center study which consisted of two distinct Study Periods plus an optional extension period in non-CD patients with CS. The 3 Study Periods (two distinct Study Periods plus an optional extension period) were as follows:
Study Period I [Week 0 (Day 1) to Week-12]: Study Period I was the dose titration period to achieve a stable therapeutic dose and to assess the efficacy and safety of osilodrostat.
The dosing regimen of osilodrostat in this study was titrated according to the following escalation sequence: osilodrostat 2 mg bid, 5 mg bid, 10 mg bid, 20 mg bid, and 30 mg bid. Dose adjustments were based on the serum cortisol values measured by the local lab at each site. Osilodrostat titration was done weekly for the initial 4-weeks, up to a maximum dose of 10 mg bid.
The mean of three 24-hour UFC (mUFC) values were measured to evaluate the efficacy in this period.
Study Period II (After Week-12 to Week-48): Study Period II was the period to assess the sustainability of efficacy and long term safety.
During Study Period II, only patients who tolerated and agreed to continue osilodrostat treatment continued on the study. The patient was administered with the stable therapeutic dose which was achieved in the Study Period I.
Optional extension period (After Week-48): Patients who continued to receive clinical benefit, as assessed by the study Investigator and who wished to enter the extension period were reconsented at Week-48. Patients who entered the extension period continued to be treated with the study drug without interruption to be assessed for efficacy and safety. Patients who continued to benefit from study treatment as assessed by the study investigator and who completed Week-72 were offered to participate in a separate long-term safety follow-up study. The optional extension period ended after all patients had completed Week-72 or had discontinued early.
Post-treatment Follow-up: All patients had 30 days safety follow-up after the last dose of study treatment.
123 studies on the registry are indexed under Cushing Syndrome; 42 are open to participants now.
This study's enrollment of 9 is below the median of 44 across 58 interventional studies indexed under Cushing Syndrome.
Browse Cushing Syndrome studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this arm took the study drug, osilodrostat.
Drug: Osilodrostat
Osirodrostat 1mg, 5mg \& 10mg in the form of film-coated tablets was used for oral administration.
Also known as: LCI699
Percent Change in the Mean Urine Free Cortisol (mUFC) at the Individual Level at Week 12
Percent change from baseline in the mUFC at the individual patient level
Time frame: Baseline, 12 weeks
Percent Change From Baseline in the mUFC at Individual Patient Level at Week 24 (Day 169) and Week 48 (Day 337)
Percent change from baseline in the mUFC at the individual patient level
Time frame: Baseline, Week 24 (day 169) and Week 48 (day 337)
Absolute Change From Baseline in the mUFC at Week 12 (Day 85), Week 24 (Day 169) and Week 48 (Day 337)
Absolute change from baseline in the mUFC
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Percentage Change From Baseline in the mUFC at Week 12 (Day 85), Week 24 (Day 169) and Week 48 (Day 337)
Percent change from baseline in the mUFC
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Percentage of Participants With mUFC Response of Complete, Partial, and Overall Response
Complete response rate = percentage of participants who had mUFC≤ ULN; Partial response rate = Percentage of participants who had mUFC\>ULN and at least 50% reduction from baseline in mUFC. Overall response rate = Percentage of participants who had mUFC ≤ ULN or at least 50% reduction from baseline.
Time frame: 12, 24 and 48 weeks
Absolute Change From Baseline in Morning Serum Cortisol at Individual Level
Absolute change from baseline in morning serum cortisol at the individual patient level
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Percentage Change From Baseline in Morning Serum Cortisol at Individual Level
Percentage change from baseline in morning serum cortisol at the individual patient level
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Absolute Change From Baseline in ACTH and Other Adrenal Steroid Hormones at Individual Level
Absolute change from baseline in several steroid hormones at individual levels: ACTH, Serum 11-deoxycorticosterone, Aldosterone, Estradiol
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Percentage Change From Baseline in ACTH and Other Adrenal Steroid Hormones at Individual Level
Percent change from baseline in several steroid hormones at individual levels: ACTH, Serum 11-deoxycorticosterone, Aldosterone, Estradiol
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Absolute Change From Baseline in Other Adrenal Steroid Hormones at Individual Levels
Absolute change from baseline in several steroid hormones at individual levels: Serum 11-deoxycortisol, Testosterone
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Percentage Change From Baseline in Other Adrenal Steroid Hormones at Individual Levels
Percent change from baseline in several steroid hormones at individual levels: Serum 11-deoxycortisol, Testosterone
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, Fasting Glucose, at Individual Level
Absolute change in cardiovascular-related metabolic parameter fasting glucose, associated with Cushing's syndrome (CS)
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, Fasting Glucose, at Individual Level
Percentasge change in cardiovascular-related metabolic parameter fasting glucose, associated with Cushing's syndrome (CS)
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, HbA1c, at Individual Level
Absolute change in cardiovascular-related metabolic parameter HbA1c associated with Cushing's syndrome (CS)
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, HbA1c, at Individual Level
Percentage change in cardiovascular-related metabolic parameter HbA1c associated with Cushing's syndrome (CS)
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Absolute Change From Baseline in Cardiovascular-related Metabolic Parameters, Cholesterol, HDL Cholesterol, LDL Cholesterol & Triglycerides, at Individual Level
Absolute change in cardiovascular-related metabolic parameters: cholesterol, HDL cholesterol, LDL cholesterol \& triglycerides, associated with Cushing's syndrome (CS)
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Percentage Change From Baseline in Cardiovascular-related Metabolic Parameters, Cholesterol, HDL Cholesterol, LDL Cholesterol & Triglycerides, at Individual Level
Percent change in cardiovascular-related metabolic parameters: cholesterol, HDL cholesterol, LDL cholesterol \& triglycerides, associated with Cushing's syndrome (CS)
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, BMI, at Individual Level
Absolute change in cardiovascular-related metabolic parameter: BMI, associated with Cushing's syndrome (CS)
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, BMI, at Individual Level
Percent change in cardiovascular-related metabolic parameter: BMI, associated with Cushing's syndrome (CS)
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, Waist Circumference, at Individual Level
Absolute change in cardiovascular-related metabolic parameter: Waist circumference, associated with Cushing's syndrome (CS)
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, Waist Circumference, at Individual Level
Percent change in cardiovascular-related metabolic parameter: Waist circumference, associated with Cushing's syndrome (CS)
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Absolute Change From Baseline in Cardiovascular-related Metabolic Parameter, Sitting Blood Pressure (BP) at Individual Level
Absolute change in cardiovascular-related metabolic parameter: sitting systolic BP \& sitting diastolic BP, associated with Cushing's syndrome (CS)
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Percentage Change From Baseline in Cardiovascular-related Metabolic Parameter, Sitting Blood Pressure (BP) at Individual Level
Percentage change in cardiovascular-related metabolic parameter: sitting systolic BP \& sitting diastolic BP, associated with Cushing's syndrome
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Total Scores in Patient-Reported Outcomes Health-related Quality of Life (QoL) as Assessed by Cushing QoL at Individual Level
The Cushing's Disease Health-Related Quality of Life Questionnaire (Cushing QoL) (version 1.0) was developed to evaluate quality of life in patients with Cushing's syndrome (Webb et al 2008). The Cushing QoL is comprised of 12 items that capture patient responses on seven concepts: daily activities, healing and pain, mood and self-confidence, social concerns, physical appearance, memory and concern about the future. Each questionnaire of the Cushing QOL has a scale of 1-5 where '1' corresponding to 'Always' or 'Very much' and '5' to 'Never' or 'Not at all'. The lower the score, the greater the impact on HRQoL. The score is the sum of all the item response and can range from 12 (worst) to 60 points (best).
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Total Scores in Patient-Reported Outcomes Health-related Quality of Life (QoL) as Assessed by Beck Depression Inventory II (BDI-ll) Depression Score at Individual Level
The Beck Depression Inventory II (BDI-II) is a patient reported instrument that consists of 21 items designed to assess the intensity of depression in clinical \& normal patients in the preceding two weeks. Each item is a list of four statements arranged in increasing severity about a particular symptom of depression. Each of 21 items corresponds to a symptom of depression and the sum of total score will be calculated where each item has a four-point scale ranging from 0 to 3, leading to a total score from zero to 63.
Time frame: Baseline, Week 12 (day 85), Week 24 (day 169) and Week 48 (day 337)
Plasma Concentrations of Osilodrostat (LCI699) at Week 0
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
Time frame: Week 0
Plasma Concentrations of Osilodrostat (LCI699) at Week 1
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
Time frame: Week 1, 2 hours post-dose
Plasma Concentrations of Osilodrostat (LCI699) at Week 2
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
Time frame: Week 2
Plasma Concentrations of Osilodrostat (LCI699) at Week 3
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
Time frame: Week 3, 2 hours post-dose
Plasma Concentrations of Osilodrostat (LCI699) at Week 4
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
Time frame: Week 4, 2 hours post-dose
Plasma Concentrations of Osilodrostat (LCI699) at Week 6
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
Time frame: Week 6, 2 hours post-dose
Plasma Concentrations of Osilodrostat (LCI699) at Week 8
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
Time frame: Week 8, 2 hours post-dose
Plasma Concentrations of Osilodrostat (LCI699) at Week 10
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
Time frame: Week 10, 2 hours post-dose
Plasma Concentrations of Osilodrostat (LCI699) at Week 12
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
Time frame: Week 12
Plasma Concentrations of Osilodrostat (LCI699) at Week 16
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
Time frame: Week 16, 2 hours post-dose
Plasma Concentrations of Osilodrostat (LCI699) at Week 20
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
Time frame: Week 20, 2 hours post-dose
Plasma Concentrations of Osilodrostat (LCI699) at Week 24
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
Time frame: Week 24, 2 hours post-dose
Planned subjects: 10 subjects Actual enrolled: 9 subjects
| Milestone | Osilodrostat |
|---|---|
| Started | 9 |
| Completed week-12 (study period i) | 7 |
| Discontinued at or prior to week-12 | 2 |
| Completed week-12, did not enter per. ii | 3 |
| Completed week-12, entered study per. ii | 4 |
| Completed week-48 (study period ii) | 2 |
| Discontinued at or prior to week48 | 2 |
| Compl. wk-48, didn't enter opt. ext. per | 0 |
| Compl. wk-48, entered opt. ext. period | 2 |
| Completed optional extension period | 0 |
| Discontinued study in optional ext. per. | 2 |
| Completed | 3 |
| Not completed | 6 |
| Withdrew: Adverse event | 4 |
| Withdrew: Subject/ guardian decision | 2 |
Percent change from baseline in the mUFC at the individual patient level
| percentage change | Osilodrostat |
|---|---|
| AIMAH- Patient 1 (n=1) | -99.0 |
| Adrenal adenoma - Patient 1 (n=1) | -97.8 |
| Adrenal adenoma - Patient 2 (n=1) | -94.5 |
| Adrenal adenoma - Patient 3 (n=1) | -91.5 |
| Adrenal adenoma - Patient 4 (n=1) | -81.8 |
| Adrenal adenoma - Patient 5 (n=1) | -52.6 |
| Ectopic corticotropin syndrome - Patient 1 (n=1) | -99.0 |
Percent change from baseline in the mUFC at the individual patient level
| percentage change | Osilodrostat |
|---|---|
| AIMAH-Patient (Pt) 1: Week (Wk) 24 (n=1) | -99.5 |
| AIMAH-Patient 1:Wk 48 (n=1) | -99.1 |
| Adrenal adenoma-Patient 2: Wk 24(n=1) | -85.2 |
| Ectopic corticotropin syndrome-Pt 1: Wk 24(n=1) | -91.6 |
| Ectopic corticotropin syndrome-Pt 1: Wk 48(n=1) | -91.0 |
Absolute change from baseline in the mUFC
| nmol/24hr | Osilodrostat |
|---|---|
| Week 12 (day 85)( n = 7) | -422.10 (-10487.5 to -157.0) |
| Week 24 (day 169) (n = 3) | -7428.10 (-9702.0 to -367.9) |
| Week 48 (day 337) (n = 2) | -8521.00 (-9640.5 to -7401.5) |
Percent change from baseline in the mUFC
| percentage change | Osilodrostat |
|---|---|
| Week 12 (day 85)( n = 7) | -94.47 (-99.0 to -52.6) |
| Week 24 (day 169) (n = 3) | -91.57 (-99.5 to -85.2) |
| Week 48 (day 337) (n = 2) | -95.04 (-99.1 to -91.0) |
Complete response rate = percentage of participants who had mUFC≤ ULN; Partial response rate = Percentage of participants who had mUFC\>ULN and at least 50% reduction from baseline in mUFC. Overall response rate = Percentage of participants who had mUFC ≤ ULN or at least 50% reduction from baseline.
| Percentage of participants | Osilodrostat |
|---|---|
| Week 12: Complete responders | 66.7 (29.9 to 92.5) |
| Week 12: Partial responders | 11.1 (0.3 to 48.2) |
| Week 12: Overall responders | 77.8 (40.0 to 97.2) |
| Week 24: Complete responders (n =3) | 66.7 (9.4 to 99.2) |
| Week 24: Partial responders (n = 3) | 33.3 (0.8 to 90.6) |
| Week 24: Overall responders (n = 3) | 100 (29.2 to 100.0) |
| Week 48: Complete responders (n = 2) | 50.0 (1.3 to 98.7) |
| Week 48: Partial responders (n = 2) | 50.0 (1.3 to 98.7) |
| Week 48: Overall responders (n = 2) | 100 (15.8 to 100.0) |
Absolute change from baseline in morning serum cortisol at the individual patient level
| nmol/L | Osilodrostat |
|---|---|
| AIMAH-Patient (Pt) 1: Week (Wk) 12 (n = 1) | -607 |
| AIMAH-Patient 1: Wk 24 (n = 1) | -571 |
| AIMAH-Patient 1: Wk 48 (n = 1) | -580 |
| Adrenal adenoma-Patient 1: Wk 12 (n =1) | -334 |
| Adrenal adenoma-Patient 2: Wk 12(n =1) | -157 |
| Adrenal adenoma-Patient 2: Wk 24 (n =1) | -135 |
| Adrenal adenoma-Patient 3: Wk 12 (n =1) | -300 |
| Adrenal adenoma-Patient 4: Wk 12 (n =1) | -30 |
| Adrenal adenoma-Patient 5: Wk 12 (n =1) | -13 |
| Ectopic corticotropin syndrome-Pt 1: Wk 12 (n =1) | -949 |
| Ectopic corticotropin syndrome-Pt 1: Wk24 (n=1) | -927 |
| Ectopic corticotropin syndrome-Pt 1: Wk48 (n=1) | -861 |
Percentage change from baseline in morning serum cortisol at the individual patient level
| percentage change | Osilodrostat |
|---|---|
| AIMAH-Patient (Pt) 1: Week (Wk) 12 (n = 1) | -73.3 |
| AIMAH-Patient 1: Wk 24 (n = 1) | -69.0 |
| AIMAH-Patient 1: Wk 48 (n = 1) | -70.0 |
| Adrenal adenoma-Patient 1: Wk 12 (n =1) | -78.0 |
| Adrenal adenoma-Patient 2: Wk 12(n =1) | -50.8 |
| Adrenal adenoma-Patient 2: Wk 24 (n =1) | -43.7 |
| Adrenal adenoma-Patient 3: Wk 12 (n =1) | -56.1 |
| Adrenal adenoma-Patient 4: Wk 12 (n =1) | -8.7 |
| Adrenal adenoma-Patient 5: Wk 12 (n =1) | -3.5 |
| Ectopic corticotropin syndrome-Pt 1: Wk 12 (n =1) | -71.4 |
| Ectopic corticotropin syndrome-Pt 1: Wk24 (n=1) | -69.7 |
| Ectopic corticotropin syndrome-Pt 1: Wk48 (n=1) | -64.7 |
Absolute change from baseline in several steroid hormones at individual levels: ACTH, Serum 11-deoxycorticosterone, Aldosterone, Estradiol
| pmol/L | ACTH | Serum 11-deoxycorticosterone | Aldosterone | Estradiol |
|---|---|---|---|---|
| AIMAH-Patient (Pt) 1 Wk 12 (n=1,1,1,1) | 0 | 2179 | 52 | 705 |
| AIMAH-Pt 1 Wk 24 (n=1,1,1,1) | 0 | 3601 | 236 | 235 |
| AIMAH-Pt 1 Wk 48 (n=1,1,1,1) | 0 | 454 | 170 | 400 |
| Adrenal adenoma-Pt 1 Wk 12 (n=1,1,1,1) | 1.1 | 2966 | -27 | -404 |
| Adrenal adenoma-Pt 2 Wk 12 (n=1,1,1,1) | 0 | 5145 | -981 | 4 |
| Adrenal adenoma-Pt 2 Wk 24(n=1,1,1,1) | 0 | 0 | 450 | -4 |
| Adrenal adenoma-Pt 3 Wk 12 (n=1,1,1,1) | 0 | 0 | -147 | 77 |
| Adrenal adenoma-Pt 4 Wk 12 (n=1,1,1,1) | 0 | 787 | 3 | 18 |
| Adrenal adenoma-Pt 5 Wk 12 (n=1,1,1,1) | 0 | 0 | 0 | -11 |
| Ectopic ACTH syndrome-Pt 1: Wk 12 (n=1,1,1,1) | -67.7 | -696 | 145 | 51 |
| Ectopic ACTH syndrome-Pt 1: Wk 24 (n=1,1,1,1) | -47.3 | -91 | 40 | -11 |
| Ectopic ACTH syndrome-Pt 1: Wk 48 (n=1,1,1,1) | 13.3 | -91 | 37 | 11 |
Percent change from baseline in several steroid hormones at individual levels: ACTH, Serum 11-deoxycorticosterone, Aldosterone, Estradiol
| percentage change | ACTH | Serum 11-deoxycorticosterone | Aldosterone | Estradiol |
|---|---|---|---|---|
| AIMAH-Patient (Pt) 1 Wk 12 (n =0,1,0,1) | — | 118.0 | — | 1282 |
| AIMAH-Pt 1 Wk 24 (n=0,1,0,1) | — | 195.1 | — | 427.3 |
| AIMAH-Pt 1 Wk 48 (n=0,1,0,1) | — | 24.6 | — | 727.3 |
| Adrenal adenoma-Pt 1 Wk 12 (n =0,0,1,1) | — | — | -13.9 | -53.7 |
| Adrenal adenoma-Pt 2 Wk 12 (n =0,0,1,1) | — | — | -100 | 1.9 |
| Adrenal adenoma-Pt 2 Wk 24 (n =0,0,1,1) | — | — | 45.9 | -1.9 |
| Adrenal adenoma-Pt 3 Wk 12 (n =0,0,1,1) | — | — | -75.0 | 513.3 |
| Adrenal adenoma-Pt 4 Wk 12 (n =0,0,1,1) | — | — | 10.0 | 120.0 |
| Adrenal adenoma-Pt 5 Wk 12 (n =0,0,0,1) | — | — | — | -100 |
| Ectopic ACTH syndrome-Pt 1: Wk 12 (n=1,1,0,1) | -71.6 | -100 | — | 72.9 |
| Ectopic ACTH syndrome-Pt 1: Wk 24 (n=1,1,0,1) | -50.0 | -13.1 | — | -15.7 |
| Ectopic ACTH syndrome-Pt 1: Wk 48 (n=1,1,0,1) | 14.1 | -13.1 | — | 15.7 |
Absolute change from baseline in several steroid hormones at individual levels: Serum 11-deoxycortisol, Testosterone
| nmol/L | Serum 11-deoxycortisol | Testosterone |
|---|---|---|
| AIMAH-Patient (Pt) 1 Wk 12 (n = 1,1) | -4.35 | 0.76 |
| AIMAH-Pt 1 Wk 24 (n = 1,1) | -8.5 | 0.66 |
| AIMAH-Pt 1 Wk 48 (n = 1,1) | -15.54 | -0.03 |
| Adrenal adenoma-Pt 1 Wk 12 (n = 1,1) | 6.91 | 0.31 |
| Adrenal adenoma-Pt 2 Wk 12 (n = 1,1) | 2.81 | 0.11 |
| Adrenal adenoma-Pt 2 Wk 24 (n = 1,1) | -0.64 | -0.35 |
| Adrenal adenoma-Pt 3 Wk 12 (n = 1,1) | 7.34 | 0.42 |
| Adrenal adenoma-Pt 4 Wk 12 (n = 1,1) | 3.5 | 0.03 |
| Adrenal adenoma-Pt 5 Wk 12 (n = 1,1) | -1.39 | 0 |
| Ectopic ACTH syndrome-Pt 1 Wk 12(n = 1,1) | -15.81 | 5.83 |
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n = 1,1) | -12.41 | -2.71 |
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n = 1,1) | -2.52 | -2.01 |
Percent change from baseline in several steroid hormones at individual levels: Serum 11-deoxycortisol, Testosterone
| percentage change | Serum 11-deoxycortisol | Testosterone |
|---|---|---|
| AIMAH-Patient (Pt) 1 Wk 12 (n=1, 1) | -17.8 | 73.1 |
| AIMAH-Pt 1 Wk 24 (n=1, 1) | -34.9 | 63.5 |
| AIMAH-Pt 1 Wk 48 (n=1, 1) | -63.7 | -2.9 |
| Adrenal adenoma-Pt 1 Wk 12 (n=1,1) | 143.7 | 100.0 |
| Adrenal adenoma-Pt 2 Wk 12 (n=1,1) | 108.9 | 10.6 |
| Adrenal adenoma-Pt 2 Wk 24 (n=1,1) | -24.8 | -33.7 |
| Adrenal adenoma-Pt 3 Wk 12 (n=1, 1) | 127.2 | 93.3 |
| Adrenal adenoma-Pt 4 Wk 12 (n=1, 1) | 267.2 | 14.3 |
| Adrenal adenoma-Pt 5 Wk 12 (n=1,1) | -43.2 | 0.0 |
| Ectopic ACTH syndrome-Pt 1 Wk 12 (n=1, 1) | -64.8 | 96.5 |
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1, 1) | -50.9 | -44.9 |
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1, 1) | -10.3 | -33.3 |
Absolute change in cardiovascular-related metabolic parameter fasting glucose, associated with Cushing's syndrome (CS)
| mmol/L | Osilodrostat |
|---|---|
| AIMAH-Patient (Pt) 1 Wk 12 (n =1) | -0.78 |
| AIMAH-Patient (Pt) 1 Wk 24 (n =1) | -0.84 |
| AIMAH-Patient (Pt) 1 Wk 48 (n =1) | -0.78 |
| Adrenal adenoma-Pt 1 Wk 12 (n =1) | 1.22 |
| Adrenal adenoma-Pt 2 Wk 12 (n =1) | -1.89 |
| Adrenal adenoma-Pt 2 Wk 24 (n =1) | 0.22 |
| Adrenal adenoma-Pt 3 Wk 12 (n =1) | -0.28 |
| Adrenal adenoma-Pt 4 Wk 12 (n =1) | -0.67 |
| Adrenal adenoma-Pt 5 Wk 12 (n =1) | -0.05 |
| Ectopic ACTH syndrome-Pt 1 Wk 12 (n =1) | -0.33 |
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n =1) | -0.39 |
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n =1) | 0.06 |
Percentasge change in cardiovascular-related metabolic parameter fasting glucose, associated with Cushing's syndrome (CS)
| percentage change | Osilodrostat |
|---|---|
| AIMAH-Patient (Pt) 1 Wk 12 (n =1) | -15.3 |
| AIMAH-Patient (Pt) 1 Wk 24 (n =1) | -16.4 |
| AIMAH-Patient (Pt) 1 Wk 48 (n =1) | -15.3 |
| Adrenal adenoma-Pt 1 Wk 12 (n =1) | 24.2 |
| Adrenal adenoma-Pt 2 Wk 12 (n =1) | -27.2 |
| Adrenal adenoma-Pt 2 Wk 24 (n =1) | 3.2 |
| Adrenal adenoma-Pt 3 Wk 12 (n =1) | -5.0 |
| Adrenal adenoma-Pt 4 Wk 12 (n =1) | -11.3 |
| Adrenal adenoma-Pt 5 Wk 12 (n =1) | -0.9 |
| Ectopic ACTH syndrome-Pt 1 Wk 12 (n =1) | -5.9 |
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n =1) | -7.0 |
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n =1) | 1.1 |
Absolute change in cardiovascular-related metabolic parameter HbA1c associated with Cushing's syndrome (CS)
| percentage of HbA1c | Osilodrostat |
|---|---|
| AIMAH-Patient (Pt) 1 Wk 12 (n=1) | -0.1 |
| AIMAH-Pt 1 Wk 24 (n=1) | -0.1 |
| AIMAH-Pt 1 Wk 48 (n=1) | -0.2 |
| Adrenal adenoma-Pt 1 Wk 12 (n=1) | 0.3 |
| Adrenal adenoma-Pt 2 Wk 12 (n=1) | -0.4 |
| Adrenal adenoma-Pt 2 Wk 24 (n=1) | -0.7 |
| Adrenal adenoma-Pt 3 Wk 12 (n=1) | -1.4 |
| Adrenal adenoma-Pt 4 Wk 12 (n=1) | -0.9 |
| Adrenal adenoma-Pt 5 Wk 12 (n=1) | -0.1 |
| Ectopic ACTH syndrome-Pt 1 Wk 12 (n=1) | 0.3 |
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1) | 0.5 |
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1) | 0.8 |
Percentage change in cardiovascular-related metabolic parameter HbA1c associated with Cushing's syndrome (CS)
| percentage change | Osilodrostat |
|---|---|
| AIMAH-Patient (Pt) 1 Wk 12 (n=1) | -1.8 |
| AIMAH-Pt 1 Wk 24 (n=1) | -1.8 |
| AIMAH-Pt 1 Wk 48 (n=1) | -3.6 |
| Adrenal adenoma-Pt 1 Wk 12 (n=1) | 6.2 |
| Adrenal adenoma-Pt 2 Wk 12 (n=1) | -6.5 |
| Adrenal adenoma-Pt 2 Wk 24 (n=1) | -11.3 |
| Adrenal adenoma-Pt 3 Wk 12 (n=1) | -20.3 |
| Adrenal adenoma-Pt 4 Wk 12 (n=1) | -12.2 |
| Adrenal adenoma-Pt 5 Wk 12 (n=1) | -1.5 |
| Ectopic ACTH syndrome-Pt 1 Wk 12 (n=1) | 5.4 |
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1) | 8.9 |
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1) | 14.3 |
Absolute change in cardiovascular-related metabolic parameters: cholesterol, HDL cholesterol, LDL cholesterol \& triglycerides, associated with Cushing's syndrome (CS)
| mmol/L | Cholesterol | HDL Cholesterol | LDL Cholesterol | Triglycerides |
|---|---|---|---|---|
| AIMAH-Patient (Pt) 1 Wk 12 (n =1,1,1,1) | -0.67 | -0.85 | 0.21 | -0.87 |
| AIMAH-Pt 1 Wk 24 (n =1,1,1,1) | -0.65 | -1.01 | 0.18 | -0.64 |
| AIMAH-Pt 1 Wk 48 (n =1,1,1,1) | -0.72 | -0.57 | -0.08 | -0.76 |
| Adrenal adenoma-Pt 1 Wk 12 (n =1,1,1,1) | -1.56 | -0.26 | -1.11 | -1.42 |
| Adrenal adenoma-Pt 2 Wk 12 (n =1,1,1,1) | -0.54 | -0.64 | -0.26 | 0.11 |
| Adrenal adenoma-Pt 2 Wk 24 (n =1,1,1,1) | 0.26 | -0.33 | 0.31 | 0.08 |
| Adrenal adenoma-Pt 3 Wk 12 (n =1,1,1,1) | -0.55 | -0.16 | -0.19 | -1.36 |
| Adrenal adenoma-Pt 4 Wk 12 (n =1,1,1,1) | 1.09 | 0.18 | 0.72 | 0.58 |
| Adrenal adenoma-Pt 5 Wk 12 (n =1,1,1,1) | -0.39 | -0.21 | -0.18 | 0.44 |
| Ectopic ACTH syndrome-Pt 1 Wk 12(n =1,1,1,1) | -0.16 | 0.16 | -0.11 | -0.47 |
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n =1,1,1,1) | -0.26 | 0.49 | -0.29 | -0.83 |
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n =1,1,1,1) | -0.08 | 0.29 | -0.31 | 0.22 |
Percent change in cardiovascular-related metabolic parameters: cholesterol, HDL cholesterol, LDL cholesterol \& triglycerides, associated with Cushing's syndrome (CS)
| percentage change | Cholesterol | HDL Cholesterol | LDL Cholesterol | Triglycerides |
|---|---|---|---|---|
| AIMAH-Patient (Pt) 1 Wk 12 (n =1,1,1,1) | -11.1 | -33.2 | 6.3 | -49.4 |
| AIMAH-Pt 1 Wk 24 (n =1,1,1,1) | -10.7 | -39.5 | 5.4 | -36.4 |
| AIMAH-Pt 1 Wk 48 (n =1,1,1,1) | -11.9 | -22.3 | -2.4 | -43.2 |
| Adrenal adenoma-Pt 1 Wk 12 (n =1,1,1,1) | -23.0 | -27.1 | -24.9 | -28.8 |
| Adrenal adenoma-Pt 2 Wk 12 (n =1,1,1,1) | -11.9 | -34.4 | -10.6 | 12.5 |
| Adrenal adenoma-Pt 2 Wk 24 (n =1,1,1,1) | 5.7 | -17.7 | 12.6 | 9.1 |
| Adrenal adenoma-Pt 3 Wk 12 (n =1,1,1,1) | -9.5 | -9.4 | -5.5 | -56.7 |
| Adrenal adenoma-Pt 4 Wk 12 (n =1,1,1,1) | 23.0 | 15.5 | 26.5 | 46.8 |
| Adrenal adenoma-Pt 5 Wk 12 (n =1,1,1,1) | -8.7 | -11.4 | -9.3 | 33.3 |
| Ectopic ACTH syndrome-Pt 1 Wk 12(n =1,1,1,1) | -3.8 | 12.4 | -4.5 | -32.0 |
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n =1,1,1,1) | -6.2 | 38.0 | -11.8 | -56.5 |
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n =1,1,1,1) | -1.9 | 22.5 | -12.6 | 15.0 |
Absolute change in cardiovascular-related metabolic parameter: BMI, associated with Cushing's syndrome (CS)
| kg/m^2 | Osilodrostat |
|---|---|
| AIMAH-Patient (Pt) 1 Wk 12 (n =1) | -0.5 |
| AIMAH-Pt 1 Wk 24 (n =1) | -2.3 |
| AIMAH-Pt 1 Wk 48 (n =1) | -1.6 |
| Adrenal adenoma-Pt 1 Wk 12 (n =1) | 0.6 |
| Adrenal adenoma-Pt 2 Wk 12 (n =1) | -1.2 |
| Adrenal adenoma-Pt 2 Wk 24 (n =1) | -3.6 |
| Adrenal adenoma-Pt 3 Wk 12 (n =1) | 0.7 |
| Adrenal adenoma-Pt 4 Wk 12 (n =1) | 0.2 |
| Adrenal adenoma-Pt 5 Wk 12 (n =1) | 0.1 |
| Ectopic ACTH syndrome-Pt 1 Wk 12(n =1) | 1.8 |
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n =1) | 3.0 |
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n =1) | 3.6 |
Percent change in cardiovascular-related metabolic parameter: BMI, associated with Cushing's syndrome (CS)
| percentage change | Osilodrostat |
|---|---|
| AIMAH-Patient (Pt) 1 Wk 12 (n =1) | -2.1 |
| AIMAH-Pt 1 Wk 24 (n =1) | -9.6 |
| AIMAH-Pt 1 Wk 48 (n =1) | -6.7 |
| Adrenal adenoma-Pt 1 Wk 12 (n =1) | 1.9 |
| Adrenal adenoma-Pt 2 Wk 12 (n =1) | -3.1 |
| Adrenal adenoma-Pt 2 Wk 24 (n =1) | -9.4 |
| Adrenal adenoma-Pt 3 Wk 12 (n =1) | 3.3 |
| Adrenal adenoma-Pt 4 Wk 12 (n =1) | 0.9 |
| Adrenal adenoma-Pt 5 Wk 12 (n =1) | 0.5 |
| Ectopic ACTH syndrome-Pt 1 Wk 12(n =1) | 7.4 |
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n =1) | 12.3 |
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n =1) | 14.8 |
Absolute change in cardiovascular-related metabolic parameter: Waist circumference, associated with Cushing's syndrome (CS)
| cm | Osilodrostat |
|---|---|
| AIMAH-Patient (Pt)1 Wk 12 (n=1) | -2.0 |
| AIMAH-Pt1 Wk 24 (n=1) | -7.5 |
| AIMAH-Pt1 Wk 48 (n=1) | -5.5 |
| Adrenal adenoma-Pt 1 Wk 12 (n=1) | -2.0 |
| Adrenal adenoma-Pt 2 Wk 12 (n=1) | -1.0 |
| Adrenal adenoma-Pt 2 Wk 24 (n=1) | -8.0 |
| Adrenal adenoma-Pt 3 Wk 12 (n=1) | -4.0 |
| Adrenal adenoma-Pt 4 Wk 12 (n=1) | 1.0 |
| Adrenal adenoma-Pt 5 Wk 12 (n=1) | -0.3 |
| Ectopic ACTH syndrome-Pt 1 Wk 12 (n=1) | 2.5 |
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1) | 11.0 |
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1) | 9.5 |
Percent change in cardiovascular-related metabolic parameter: Waist circumference, associated with Cushing's syndrome (CS)
| percentage change | Osilodrostat |
|---|---|
| AIMAH-Patient (Pt)1 Wk 12 (n=1) | -2.4 |
| AIMAH-Pt1 Wk 24 (n=1) | -9.0 |
| AIMAH-Pt1 Wk 48 (n=1) | -6.6 |
| Adrenal adenoma-Pt 1 Wk 12 (n=1) | -1.8 |
| Adrenal adenoma-Pt 2 Wk 12 (n=1) | -0.9 |
| Adrenal adenoma-Pt 2 Wk 24 (n=1) | -7.1 |
| Adrenal adenoma-Pt 3 Wk 12 (n=1) | -4.9 |
| Adrenal adenoma-Pt 4 Wk 12 (n=1) | 1.1 |
| Adrenal adenoma-Pt 5 Wk 12 (n=1) | -0.4 |
| Ectopic ACTH syndrome-Pt 1 Wk 12 (n=1) | 2.9 |
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1) | 12.9 |
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1) | 11.1 |
Absolute change in cardiovascular-related metabolic parameter: sitting systolic BP \& sitting diastolic BP, associated with Cushing's syndrome (CS)
| mmHg | Sitting Systolic BP | Sitting Diastolic BP |
|---|---|---|
| AIMAH-Patient (Pt) 1Wk 12 (n =1, 1) | -44.3 | -31.0 |
| AIMAH-Patient (Pt) 1 Wk 24 (n =1, 1) | -48.34 | -32.66 |
| AIMAH-Patient (Pt) 1 Wk 48 (n =1, 1) | -40.34 | -19.0 |
| Adrenal adenoma-Pt 1 Wk 12 (n=1,1) | 11.67 | -3.67 |
| Adrenal adenoma-Pt 2 Wk 12 (n=1,1) | -50.67 | -37.0 |
| Adrenal adenoma-Pt 2 Wk 24 (n=1,1) | -32.33 | -26.66 |
| Adrenal adenoma-Pt 3 Wk 12 (n=1,1) | -16.0 | -6.67 |
| Adrenal adenoma-Pt 4 Wk 12 (n=1,1) | -6.67 | 7.33 |
| Adrenal adenoma-Pt 5 Wk 12 (n=1,1) | 11.0 | 3.33 |
| Ectopic ACTH syndrome-Pt 1 Wk 12(n=1,1) | -17.67 | -13.67 |
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1,1) | 4.33 | 4.0 |
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1,1) | -1.0 | -0.67 |
Percentage change in cardiovascular-related metabolic parameter: sitting systolic BP \& sitting diastolic BP, associated with Cushing's syndrome
| percentage change | Sitting Systolic BP | Sitting Diastolic BP |
|---|---|---|
| AIMAH-Patient (Pt) 1Wk 12 (n =1, 1) | -31.1 | -32.5 |
| AIMAH-Patient (Pt) 1 Wk 24 (n =1, 1) | -33.9 | -34.3 |
| AIMAH-Patient (Pt) 1 Wk 48 (n =1, 1) | -28.3 | -19.9 |
| Adrenal adenoma-Pt 1 Wk 12 (n=1,1) | 9.2 | -4.1 |
| Adrenal adenoma-Pt 2 Wk 12 (n=1,1) | -31.3 | -33.2 |
| Adrenal adenoma-Pt 2 Wk 24 (n=1,1) | -20.0 | -23.9 |
| Adrenal adenoma-Pt 3 Wk 12 (n=1,1) | -12.3 | -8.9 |
| Adrenal adenoma-Pt 4 Wk 12 (n=1,1) | -4.3 | 9.9 |
| Adrenal adenoma-Pt 5 Wk 12 (n=1,1) | 9.3 | 5.1 |
| Ectopic ACTH syndrome-Pt 1 Wk 12(n=1,1) | -14.1 | -16.5 |
| Ectopic ACTH syndrome-Pt 1 Wk 24 (n=1,1) | 3.4 | 4.8 |
| Ectopic ACTH syndrome-Pt 1 Wk 48 (n=1,1) | -0.8 | -0.8 |
The Cushing's Disease Health-Related Quality of Life Questionnaire (Cushing QoL) (version 1.0) was developed to evaluate quality of life in patients with Cushing's syndrome (Webb et al 2008). The Cushing QoL is comprised of 12 items that capture patient responses on seven concepts: daily activities, healing and pain, mood and self-confidence, social concerns, physical appearance, memory and concern about the future. Each questionnaire of the Cushing QOL has a scale of 1-5 where '1' corresponding to 'Always' or 'Very much' and '5' to 'Never' or 'Not at all'. The lower the score, the greater the impact on HRQoL. The score is the sum of all the item response and can range from 12 (worst) to 60 points (best).
| scores on a scale | Osilodrostat |
|---|---|
| AIMAH-Patient 1: Week (Wk) 12 (n=1) | 48 |
| AIMAH-Patient 1: Wk 24 (n=1) | 51 |
| AIMAH-Patient 1: Wk 48 (n=1) | 47 |
| Adrenal adenoma-Patient 1: Wk 12(n=1) | 29 |
| Adrenal adenoma-Patient 2: Wk 12(n=1) | 18 |
| Adrenal adenoma-Patient 2: Wk 24 (n = 1) | 22 |
| Adrenal adenoma-Patient 3: Wk 12 (n =1) | 29 |
| Adrenal adenoma-Patient 4: Wk 12 (n =1) | 38 |
| Adrenal adenoma-Patient 5: Wk 12 (n=1) | 45 |
| Ectopic corticotropin syndrome-Pt 1: Wk 12 (n =1) | 31 |
| Ectopic corticotropin syndrome-Pt 1: Wk 24 (n =1) | 33 |
| Ectopic corticotropin syndrome-Pt 1: Wk 48 (n =1) | 23 |
The Beck Depression Inventory II (BDI-II) is a patient reported instrument that consists of 21 items designed to assess the intensity of depression in clinical \& normal patients in the preceding two weeks. Each item is a list of four statements arranged in increasing severity about a particular symptom of depression. Each of 21 items corresponds to a symptom of depression and the sum of total score will be calculated where each item has a four-point scale ranging from 0 to 3, leading to a total score from zero to 63.
| scores on a scale | Osilodrostat |
|---|---|
| AIMAH-Patient 1: Week (Wk) 12 (n =1) | 4 |
| AIMAH-Patient 1: Wk 24 (n =1) | 15 |
| AIMAH-Patient 1: Wk 48 (n =1) | 12 |
| Adrenal adenoma-Patient 1: Wk 12 (n =1) | 33 |
| Adrenal adenoma-Patient 2: Wk 12 (n =1) | 35 |
| Adrenal adenoma-Patient 2: Wk 24 (n =1) | 37 |
| Adrenal adenoma-Patient 3: Wk 12 (n =1) | 30 |
| Adrenal adenoma-Patient 4: Wk 12 (n =1) | 26 |
| Adrenal adenoma-Patient 5: Wk 12 (n =1) | 10 |
| Ectopic corticotropin syndrome-Pt 1: Wk 12 (n =1) | 9 |
| Ectopic corticotropin syndrome-Pt 1: Wk 24 (n =1) | 10 |
| Ectopic corticotropin syndrome-Pt 1: Wk 48 (n =1) | 22 |
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
| ng/mL | Osilodrostat 1mg | Osilodrostat 2mg | Osilodrostat 3mg | Osilodrostat 5mg |
|---|---|---|---|---|
| Week 0: 0.75 hour post-dose | 0.971 ± NA | 0.405 ± 0.673 | — | — |
| Week 0: 2 hours post-dose | 5.11 ± NA | 5.29 ± 4.94 | — | — |
| Week 0: 4 hours post-dose | 3.77 ± NA | 8.12 ± 2.36 | — | — |
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
| ng/mL | Osilodrostat 1mg | Osilodrostat 2mg | Osilodrostat 3mg | Osilodrostat 5mg |
|---|---|---|---|---|
| Plasma Concentrations of Osilodrostat (LCI699) at Week 1 | 10.9 ± NA | 10.5 ± 6.57 | 21.3 ± NA | 22.3 ± 14.2 |
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
| ng/mL | Osilodrostat 1mg | Osilodrostat 2mg | Osilodrostat 3mg | Osilodrostat 5mg |
|---|---|---|---|---|
| Week 2: 0.75 hour post-dose | 3.89 ± 2.76 | 3.69 ± 3.3 | 33.1 ± 19.2 | 34.9 ± 34.6 |
| Week 2: 2 hours post-dose | 8.93 ± 2.36 | 14.3 ± 7.64 | 21.3 ± 4.53 | 33.6 ± 8.84 |
| Week 2: 4 hours post-dose | 7.01 ± 2.69 | 11.1 ± NA | 13.6 ± 3.89 | 29.2 ± 0.354 |
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
| ng/mL | Osilodrostat 1mg | Osilodrostat 2mg | Osilodrostat 3mg | Osilodrostat 5mg |
|---|---|---|---|---|
| Plasma Concentrations of Osilodrostat (LCI699) at Week 3 | 7.09 ± 2.07 | 7.62 ± NA | 23.2 ± NA | 37.8 ± 0.849 |
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
| ng/mL | Osilodrostat 1mg | Osilodrostat 2mg | Osilodrostat 3mg | Osilodrostat 5mg |
|---|---|---|---|---|
| Plasma Concentrations of Osilodrostat (LCI699) at Week 4 | 4.08 ± 2.61 | 9.91 ± 3.53 | — | 24.0 ± 21.00 |
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
| ng/mL | Osilodrostat 1mg | Osilodrostat 2mg | Osilodrostat 3mg | Osilodrostat 5mg |
|---|---|---|---|---|
| Plasma Concentrations of Osilodrostat (LCI699) at Week 6 | 6.74 ± 2.42 | 12.7 ± 9.08 | — | 31.7 ± NA |
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
| ng/mL | Osilodrostat 1mg | Osilodrostat 2mg | Osilodrostat 3mg | Osilodrostat 5mg |
|---|---|---|---|---|
| Plasma Concentrations of Osilodrostat (LCI699) at Week 8 | 3.35 ± 2.75 | 13.9 ± NA | — | — |
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
| ng/mL | Osilodrostat 1mg | Osilodrostat 2mg | Osilodrostat 3mg | Osilodrostat 5mg |
|---|---|---|---|---|
| Plasma Concentrations of Osilodrostat (LCI699) at Week 10 | 4.73 ± 1.26 | 11.3 ± 4.57 | — | — |
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
| ng/mL | Osilodrostat 1mg | Osilodrostat 2mg | Osilodrostat 3mg | Osilodrostat 5mg |
|---|---|---|---|---|
| Week 12: 0.75 hour post-dose | 0.382 ± 0.171 | 3.1 ± NA | — | — |
| Week 12: 2 hours post-dose | 4.62 ± 2.51 | 9.98 ± NA | — | — |
| Week 12: 4 hours post-dose | 3.58 ± 2.3 | 6.57 ± NA | — | — |
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
| ng/mL | Osilodrostat 1mg | Osilodrostat 2mg | Osilodrostat 3mg | Osilodrostat 5mg |
|---|---|---|---|---|
| Plasma Concentrations of Osilodrostat (LCI699) at Week 16 | 5.71 ± 1.33 | — | — | — |
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
| ng/mL | Osilodrostat 1mg | Osilodrostat 2mg | Osilodrostat 3mg | Osilodrostat 5mg |
|---|---|---|---|---|
| Plasma Concentrations of Osilodrostat (LCI699) at Week 20 | 0.794 ± NA | — | — | — |
Osilodrostat plasma concentration data at each time-point were summarized by incident dose. About a half of pre-dose concentration data were excluded from analysis due to deviation from the pre-defined acceptable time window.
| ng/mL | Osilodrostat 1mg | Osilodrostat 2mg | Osilodrostat 3mg | Osilodrostat 5mg |
|---|---|---|---|---|
| Plasma Concentrations of Osilodrostat (LCI699) at Week 24 | 6.51 ± 2.14 | — | — | — |
Collected over Adverse events (AEs) were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of 68.0 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Osilodrostat | 0/9 (0%) | 4/9 (44.4%) | 9/9 (100%) |
| Event | Osilodrostat |
|---|---|
| Adrenal insufficiencyEndocrine disorders | 2/9 |
| Myocardial infarctionCardiac disorders | 1/9 |
| PneumoniaInfections and infestations | 1/9 |
| Psychiatric symptomPsychiatric disorders | 1/9 |
| Event | Osilodrostat |
|---|---|
| Adrenal insufficiencyEndocrine disorders | 5/9 |
| MalaiseGeneral disorders | 3/9 |
| NasopharyngitisInfections and infestations | 3/9 |
| Gamma-glutamyltransferase increasedInvestigations | 3/9 |
| ConstipationGastrointestinal disorders | 2/9 |
| Alanine aminotransferase increasedInvestigations | 2/9 |
| Aspartate aminotransferase increasedInvestigations | 2/9 |
| Blood alkaline phosphatase increasedInvestigations | 2/9 |
| HypokalaemiaMetabolism and nutrition disorders | 2/9 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 2/9 |
Full Analysis Set (FAS): Comprised of all enrolled patients who received at least one dose of osilodrostat.
| Age, Continuous(years) | Osilodrostat |
|---|---|
| Mean | 51.0 ± 18.17 |
| Sex: Female, Male(Participants) | Osilodrostat |
|---|---|
| Female | 7 |
| Male | 2 |
| Race/Ethnicity, Customized(participants) | Osilodrostat |
|---|---|
| Japanese | 9 |
| Type of disease(Participants) | Osilodrostat |
|---|---|
| ACTH-Independent Macronodular Adrena;l Hyperplasia | 1 |
| Adrenal Adenoma | 5 |
| Ectopic Corticotropin Syndrome | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Sep 2015 to primary completion in Jun 2018, 32 months.
Results were first posted in Mar 2020, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osilodrostat